Observations on the expression of human papillomavirus major capsid protein in HeLa cells

Cancer Cell International

Shuo-Shuang Xiao³  Gui-Cheng Tang³  Jia-Hua Li³  Mohammad Amjad Kamal²  Gohar Mushtaq¹  Zhi-Ying Li⁴  Bing-Bing Fu³  Chang-Yi Xiao³ 

[1] Department of Biochemistry, College of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia;Enzymoic, 7 Peterlee Place, Hebersham NSW 2770, Australia;Tumor Research Institute, China Three Gorges University, Yichang 443002, Hubei Province, People’s Republic of China;Department of Gynaecology and Obstetrics, The Second Clinical Medical College of China Three Gorges University, Yichang 443000, Hubei Province, People’s Republic of China

关键词: Expression;    Major capsid protein;    Human papillomavirus;    Cervical cancer;    HeLa cells;   

Others  :  1219354
DOI  :  10.1186/s12935-015-0206-0

 received in 2014-09-23, accepted in 2015-05-14,  发布年份 2015

【 摘 要 】

Background

The goal of this study was to identify the nature of the inclusion bodies that have been found in HeLa cells (cervical cancer immortal cell line) by electron microscope and to determine whether the major capsid protein (L1) of human papillomavirus (HPV) can be expressed in HPV-positive uterine cervix cancer cells.

Methods

HPV L1 protein expression in HeLa cells was detected with anti-HPV L1 multivalent mice monoclonal antibody and rabbit polyclonal anti-HPV L1 antibody by ELISA, light microscope immunohistochemistry, electron microscope immunocytochemistry and Western blotting assays. Reverse transcriptional PCR (RT-PCR) was performed to detect the transcription of L1 mRNA in HeLa cells. The immortalized human keratinocyte HeCat was used as the negative control.

Results

HPV L1 proteins reacted positively in the lysate of HeLa cells by ELISA assays. HRP labeled light microscope immunohistochemistry assay showed that there was a strong HPV L1 positive reaction in HeLa cells. Under the electron microscope, irregular shaped inclusion bodies, assembled by many small and uniform granules, had been observed in the cytoplasm of some HeLa cells. These granules could be labeled by the colloidal gold carried by HPV L1 antibody. The Western blotting assay showed that there was a L1 reaction strap at 80–85 kDa in the HeLa cell lysates, hence demonstrating the existence of HPV18 L1 in HeLa cells. RT-PCR assay showed that the L1 mRNA was transcribed in HeLa cells.

Conclusions

The inclusion bodies found in the cytoplasm of HeLa cells are composed of HPV18 L1 protein. Since HeLa cell line is a type of cervical cancer cells, this implies that HeLa cells have the ability to express HPV L1 proteins.

【 授权许可】

   
2015 Xiao et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

Fig. 9.

【 参考文献 】

• [1]Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE et al.. Immunological analyses of human papillomavirus capsids. Vaccine. 2001; 19:1783-93.
• [2]Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I et al.. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol. 2003; 77:4635-45.
• [3]Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology. 2007; 369:375-88.
• [4]Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol. 2010; 118 Suppl 1:S8-11.
• [5]Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther. 2012; 17:425-34.
• [6]Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 Suppl 5:F123-38.
• [7]Fehrmann F, Klumpp DJ, Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol. 2003; 77:2819-31.
• [8]Wilson R, Fehrmann F, Laimins LA. Role of the E1–E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol. 2005; 79:6732-40.
• [9]Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004; 68:362-72.
• [10]Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol Cell Biol. 2005; 25:8643-55.
• [11]Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005; 32 Suppl 1:S7-15.
• [12]Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110:525-41.
• [13]Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers. 2007; 23:297-313.
• [14]Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P et al.. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer. 2001; 92:9-17.
• [15]Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T et al.. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer. 2008; 114:83-8.
• [16]Lee SJ, Lee AW, Kang CS, Park JS, Park DC, Ki EY et al.. Clinicopathological implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16-positive cervical cytology. Int J Med Sci. 2014; 11:80-6.
• [17]Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D et al.. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by Spectral Karyotyping. Cancer Res. 1999; 59:141-50.
• [18]Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984; 3:1151-7.
• [19]Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A et al.. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985; 314(6006):111-4.
• [20]Meissner JD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol. 1999; 80:1725-33.
• [21]Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 2007; 39:2006-11.
• [22]Wu TC, Hsieh ST, Purow BW, Kurman RJ. Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice. J Virol Meth. 1997; 65:287-98.
• [23]Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U. Doeberitz Mv. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene. 2002; 21:419-26.
• [24]Shi YM, Xiao CY, Ye H, Wang YQ, Wu JF. The detection of HPV16 L1 from cervical tissue specimen. Basic Clin Med. 2010; 30:807-10.
• [25]Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI. The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet. 2005; 158:27-34.
• [26]Zhao X, Fay J, Lambkin H, Schwartz S. Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology. 2007; 369:351-63.
• [27]Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 2011; 85:8080-92.
• [28]Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO J. 2002; 21:4754-62.
• [29]Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000; 5:557-67.
• [30]Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ et al.. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol. 2008; 36:864-7.
• [31]Xiao W, Bian M, Ma L, Liu J, Chen Y, Yang B et al.. Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions. Acta Cytol. 2010; 54:661-7.
• [32]Jiang BL, Xiao CY, Yuan TN, Ye H, Wang YQ, Li JH et al.. Humoral immunity characteristics of a conserved sequence on the C-terminal region of the human papillomavirus major protein Ll. Immunological J. 2009; 25:239-42.
• [33]Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Xu X et al.. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce interference among component types. Vaccine. 2010; 28:3479-87.